Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults

@article{Jones2011CholesterolloweringEO,
  title={Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults},
  author={Mitchell Lawrence Jones and Christopher J. Martoni and Mathieu Parent and Satya Prakash},
  journal={British Journal of Nutrition},
  year={2011},
  volume={107},
  pages={1505 - 1513}
}
Several studies have reported limited or no reduction in serum cholesterol in response to probiotic formulations. Recently, probiotics have shown promise in treating metabolic disease due to improved strain selection and delivery technologies. The aim of the present study was to evaluate the cholesterol-lowering efficacy of a yoghurt formulation containing microencapsulated bile salt hydrolase (BSH)-active Lactobacillus reuteri NCIMB 30242, taken twice per d over 6 weeks, in… 
View on Cambridge Press
cambridge.org
240 Citations
Highly Influential Citations
6
Background Citations
72
Methods Citations
6
Results Citations
3

240 Citations

Citation Type

Citation Type

Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial
TLDR
The present results suggest that the deconjugation of intraluminal bile acids results in reduced absorption of non-cholesterol sterols and indicate that L. reuteri NCIMB 30242 capsules may be useful as an adjunctive therapy for treating hypercholesterolemia.
Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: a randomized, placebo-controlled, double-blind study.
Effect of Daily Consumption of Lactobacillus reuteri CRL 1098 on Cholesterol Reduction in Hypercholesterolemic Subjects
TLDR
It is suggested that low amounts of yogurt and low doses of the CRL 1098 strain (106 CFU) are sufficient to reduce total and LDL-cholesterol levels in hypercholesterolemic subjects.
Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial.
TLDR
This is the first report of increased circulating 25-hydroxyvitamin D in response to oral probiotic supplementation and the effects on fat-soluble vitamins was previously unknown.
Cholesterol-lowering efficacy of Lactobacillus plantarum CECT 7527, 7528 and 7529 in hypercholesterolaemic adults
TLDR
The present results showed that the biofunctionality of L. plantarum (CECT 7527, CECT 7528 and CECT7529) is proportional to the cardiovascular risk of the patient, having a better effect in patients with higher levels of cholesterol.
Hypolipidemic Effects and Safety of Lactobacillus Reuteri 263 in a Hamster Model of Hyperlipidemia
TLDR
Probiotic strain Lr263 could be a potential agent with a hypolipidemic pharmacological effect in hamsters with hyperlipidemia induced by a high-cholesterol diet and had few subchronic toxic effects.
Changes in bile acids, FGF-19 and sterol absorption in response to bile salt hydrolase active L. reuteri NCIMB 30242
TLDR
This is the first clinical support showing that a BSH-active probiotic can significantly and rapidly influence BA metabolism and may prove useful in chronic diseases beyond hypercholesterolemia.
Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules: a post-hoc analysis of a randomized controlled trial
TLDR
L. reuteri NCIMB 30242 capsules appear to be well tolerated and potentially beneficial for GI health status and further clinical investigation is warranted for the treatment of functional GI disorders.
Probiotic Characterization of Cholesterol-Lowering Lactobacillus fermentum MJM60397
TLDR
Results indicate that L. fermentum MJM60397 could be developed into a potential probiotic for reducing the serum cholesterol levels and bile acid absorption and increased excretion of bile acids in the feces.
Lactobacillus reuteri A9 and Lactobacillus mucosae A13 isolated from Chinese superlongevity people modulate lipid metabolism in a hypercholesterolemia rat model.
TLDR
It is hypothesized that probiotics isolated from the residents of so-called 'longevity villages' would have cholesterol-reducing effects on rats with hypercholesterolemia and the composition of gut microbiota was recovered by oral gavage in both experimental groups, and the destroyed diversity of Gut microbiota was relieved.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 59 REFERENCES
Orally delivered microencapsulated live probiotic formulation lowers serum lipids in hypercholesterolemic hamsters.
TLDR
Treatment with microencapsulated LF11976 formulation produces significant reductions in serum total cholesterol, LDL cholesterol, and serum triglyceride levels in diet-induced hypercholesterolemic hamsters, suggesting the potential of the oral microencapulated probiotic cell formulation as a functional nutritional alternative for managing excessive serum cholesterol and triglyceride Levels.
Microencapsulated bile salt hydrolase producing Lactobacillus reuteri for oral targeted delivery in the gastrointestinal tract
TLDR
Results show excellent potential for this highly BSH-active microencapsulation system in vitro, highlighted by improved viability and substrate utilization in simulated GI transit.
Cholesterol lowering in pigs through enhanced bacterial bile salt hydrolase activity
TLDR
Based on limited data, it was suggested that the administered Lactobacillus species had caused a temporary shift within the indigenous LactOBacillus population rather than permanently colonizing the intestinal tract.
Hypocholesterolaemic effect of dietary inclusion of two putative probiotic bile salt hydrolase-producing Lactobacillus plantarum strains in Sprague–Dawley rats
TLDR
Results suggest that the indigenous L. plantarum Lp91 strain has the potential to be explored as a probiotic in the management of hypercholesterolaemia.
Microencapsulated Genetically Engineered Lactobacillus plantarum 80 (pCBH1) for Bile Acid Deconjugation and Its Implication in Lowering Cholesterol
TLDR
It is shown that microencapsulated Lactobacillus plantarum 80 (pCBH1) cells can efficiently break down and remove bile acids, and establishes a basis for their use in lowering blood serum cholesterol.
Hypocholesterolemic effects of Lactobacillus plantarum KCTC3928 by increased bile acid excretion in C57BL/6 mice.
Lactobacillus effects on cholesterol: in vitro and in vivo results.
TLDR
In ingestion of commercially available Lactobacillus tablets, which contain about 2 X 10(6) cfu/tablet of L. acidophilus and L. bulgaricus cells in a dose of four tablets daily did not affect serum lipoprotein concentrations, confirming that assay results were quite reliable.
A double-blind placebo-controlled study of the effects of Lactobacillus acidophilus on plasma lipids
TLDR
Despite the ability in vitro for L. acidophilus to reduce cholesterol, no effect was seen in volunteers and no changes in serum lipids seen throughout the study.
Evaluation of the effects of a new fermented milk product (Gaio) on primary hypercholesterolemia
TLDR
The fermented milk (Gaio®) produced a small but statistically significant decrease in total and LDL-cholesterol mean, however, not all subjects seem to respond to the product, and a few subjects showed a cholesterol increment.
Yoghurt enriched with Lactobacillus acidophilus does not lower blood lipids in healthy men and women with normal to borderline high serum cholesterol levels
TLDR
Yoghurt enriched with Lactobacillus acidophilus L-1 does not lower serum cholesterol in men and women with normal to borderline high cholesterol levels.
...
1
2
3
4
5
...